Summer 2026, Fall 2026

Brand Protection Analytics Co-op

Posted on 5/16/2026

Deadline 5/27/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$22 - $32/hr

No H1B Sponsorship

Bridgewater Township, NJ, USA

Hybrid

Category
Data & Analytics (2)
,
Required Skills
Data Science
Machine Learning
Business Analytics
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Completion of Undergraduate Freshman year at an accredited University is required.
  • Currently pursuing a bachelor’s and master’s degree in Data Science, Economics, Statistics, Computer Science, Business Analytics or a related technical field.
  • Have a cumulative GPA of 2.8 or higher, which is reflective of all college coursework.
  • Proficiency in Microsoft PowerPoint, Excel, and Access.
  • Strong quantitative skills and attention to detail.
  • Ability to analyze and manipulate data effectively.
Responsibilities
  • Develop and deliver impactful data-driven insights to protect patients from illicit trade.
  • Collaborate with data engineers, data visualization developers, and data scientists.
  • Support AI tool development by collecting and preparing training data, documenting functional and data requirements, and executing user acceptance testing (UAT).
  • Analyze and assess risks and threats from counterfeiting, diversion, and tampering.
  • Apply signal-detection methods, machine learning, and AI to identify illicit trade signals.
  • Develop analytics-based reports and presentations using PowerBI.
  • Support the Product Protection Forensics Laboratory by: Analyzing counterfeit and diverted samples using forensic analysis methods; Recording sample and test data in the Laboratory Information Management System (LIMS); Support communications and training on product protection security features, including creating presentations and training materials; Support with ad-hoc projects as needed.
Desired Qualifications
  • Knowledge of open-source programming languages such as R and Python.
  • Experience with database management tools.
  • Permanently authorized to work in the United States, must not require sponsorship of an employment visa at the time of application or in the future. Students currently on CPT, OPT, or STEM OPT usually requires future sponsorship for long term employment and do not meet the requirements for this program unless eligible for an alternative long-term status that does not require company sponsorship.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Oncology momentum from DARZALEX, CARVYKTI, and RYBREVANT is lifting 2026 growth.
  • IMAAVY and CAPLYTA expand J&J into rare immunology and neuropsychiatry.
  • Shockwave C2 Aero and Atraverse strengthen MedTech leadership in coronary and atrial procedures.

What critics are saying

  • STELARA biosimilar erosion will keep crushing immunology revenue and margins through 2026.
  • Oncology growth depends heavily on CARVYKTI and RYBREVANT, creating concentrated execution risk.
  • Orthopaedics separation, if delayed, will distract management and expose stranded-cost pressure.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing reliance on any single product cycle.
  • It combines blockbuster pharmaceuticals with procedural devices like Shockwave and ETHICON.
  • The company leverages 1886 heritage, AAA credit, and 64 consecutive dividend increases.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.